SRZN - Surrozen, Inc./DE

27.74
0.340   1.226%

Share volume: 101,232
Last Updated: 03-10-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$27.40
0.34
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 42%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.59%
1 Month
12.76%
3 Months
16.51%
6 Months
143.12%
1 Year
144.41%
2 Year
108.26%
Key data
Stock price
$27.74
P/E Ratio 
0.00
DAY RANGE
$26.15 - $29.47
EPS 
-$28.02
52 WEEK RANGE
$5.90 - $29.60
52 WEEK CHANGE
$131.94
MARKET CAP 
110.329 M
YIELD 
N/A
SHARES OUTSTANDING 
8.571 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
0.89
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$112,974
AVERAGE 30 VOLUME 
$83,425
Company detail
CEO: Craig C. Parker
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Recent news